News | News By Subject | News by Disease News By Date | Search News

Encephalitis News Articles

Get Our FREE
Industry eNewsletter
email:    
Top Breaking News
AmerisourceBergen Corporation (ABC) the “Pony to Ride” for Biosimilar Opportunities, Says UBS     3/16/2015
Analyst: Current Crop of Biotech IPOs a Mixed Bag of Low Market Caps, Little Data     12/3/2014
Best Value In Biotech? Actavis (ACT), Says UBS     11/17/2014
Ocera Therapeutics, Inc. (OCRX)’s New HE Drug Could Pull Stock Up Out Of Rut: Cowen     10/24/2014
US Panel Backs New Intercell AG Encephalitis Vaccine     6/25/2009
Salix Pharmaceuticals, Ltd. (SLXP) Says Rifaximin Demonstrates Highly Statistically Significant Results in Prevention of Hepatic Encephalopathy in Pivotal Phase 3 Study     10/6/2008
Intercell AG Vaccine Has Positive Results In Trial     8/24/2006
Positive Results For Intercell AG's Japanese Encephalitis Virus Vaccine In Pivotal Clinical Trial; Phase III Meets Primary Endpoint     6/1/2006
Medicis Pharmaceutical (MRX) Announces FDA Approval Of AMMONUL For Urea Cycle Disorder     2/18/2005

News from Around the Web

Press Releases
Intercell AG Making Strides Towards Imminent Approval Of Its Japanese Encephalitis Vaccine In The United States     10/21/2008
Acambis (ACAM) Says Japanese Encephalitis Trial Positive     10/30/2006
Acambis PLC (ACAM) Completes Enrollment For Japanese Encephalitis Phase III Trials     4/19/2006
Acambis PLC (ACAM) Joins Forces With Bharat Biotech To Address Unmet Need For JE Vaccine In India     11/7/2005
OctoPlus B.V. And SingVax Pte Ltd Announce Collaboration To Develop Single-Shot Japanese Encephalitis Vaccine     9/26/2005
CEL-SCI (CVM) Release: CEL-1000 Peptide Effective Against Viral Encephalitis In Mice     4/4/2005
Crucell N.V. (CRXL) Signs Commercial PER.C6 License Agreement With SingVax Pte Ltd For Vaccines Against Japanese Encephalitis     3/22/2005
Crucell N.V. (CRXL) Signs Commercial PER.C6 License Agreement With SingVax For Vaccines Against Japanese Encephalitis     3/22/2005
GenoMed, Inc.'s Treatment Showing 100% Response Rate Among Immunocompetent Patients; Nationwide Trial Gaining Momentum     4/23/2004

//-->